申请人:HEPTARES THERAPEUTICS LTD
公开号:WO2021186166A1
公开(公告)日:2021-09-23
The disclosures herein relate to novel compounds of formula (1 ): and salts thereof, wherein Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.
本公开涉及式(1)的新化合物及其盐,其中Q、W、X、Y、Z、AA1、AA2、AA3、AA4、AA5、AA6、AA7、AA8、AA9、LysR、R1、R2和n在此处有定义,并其在治疗、预防、改善、控制或减少与胰高血糖素样肽(GLP)受体相关的疾病风险方面的用途。